221 related articles for article (PubMed ID: 24931162)
21. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
22. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
23. SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer.
Martin E; Agazie YM
Mol Cancer Res; 2021 Nov; 19(11):1946-1956. PubMed ID: 34389690
[TBL] [Abstract][Full Text] [Related]
24. Nuclear Shp2 directs normal embryo implantation via facilitating the ERα tyrosine phosphorylation by the Src kinase.
Ran H; Kong S; Zhang S; Cheng J; Zhou C; He B; Xin Q; Lydon JP; DeMayo FJ; Feng GS; Xia G; Lu Z; Wang C; Wang H
Proc Natl Acad Sci U S A; 2017 May; 114(18):4816-4821. PubMed ID: 28424251
[TBL] [Abstract][Full Text] [Related]
25. SHP2 positively regulates TGFβ1-induced epithelial-mesenchymal transition modulated by its novel interacting protein Hook1.
Li S; Wang L; Zhao Q; Liu Y; He L; Xu Q; Sun X; Teng L; Cheng H; Ke Y
J Biol Chem; 2014 Dec; 289(49):34152-60. PubMed ID: 25331952
[TBL] [Abstract][Full Text] [Related]
26. Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma.
Sturla LM; Zinn PO; Ng K; Nitta M; Kozono D; Chen CC; Kasper EM
Br J Cancer; 2011 Oct; 105(8):1235-43. PubMed ID: 21934682
[TBL] [Abstract][Full Text] [Related]
27. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).
Hartman Z; Geldenhuys WJ; Agazie YM
J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694
[TBL] [Abstract][Full Text] [Related]
28. M-CSF secreted by gastric cancer cells exacerbates the progression of gastric cancer by increasing the expression of SHP2 in tumor-associated macrophages.
Zhang S; Ren D; Hou H; Yao L; Yuan H
Aging (Albany NY); 2023 Dec; 15(24):15525-15534. PubMed ID: 38159254
[TBL] [Abstract][Full Text] [Related]
29. A novel role of vascular endothelial cadherin in modulating c-Src activation and downstream signaling of vascular endothelial growth factor.
Ha CH; Bennett AM; Jin ZG
J Biol Chem; 2008 Mar; 283(11):7261-70. PubMed ID: 18180305
[TBL] [Abstract][Full Text] [Related]
30. G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphatase.
Futami M; Zhu QS; Whichard ZL; Xia L; Ke Y; Neel BG; Feng GS; Corey SJ
Blood; 2011 Jul; 118(4):1077-86. PubMed ID: 21636860
[TBL] [Abstract][Full Text] [Related]
31. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
Xiao Y; Li Y; Tao H; Humphries B; Li A; Jiang Y; Yang C; Luo R; Wang Z
Cancer Lett; 2018 Oct; 433():199-209. PubMed ID: 29964204
[TBL] [Abstract][Full Text] [Related]
32. Dual Mechanisms of LYN Kinase Dysregulation Drive Aggressive Behavior in Breast Cancer Cells.
Tornillo G; Knowlson C; Kendrick H; Cooke J; Mirza H; Aurrekoetxea-Rodríguez I; Vivanco MDM; Buckley NE; Grigoriadis A; Smalley MJ
Cell Rep; 2018 Dec; 25(13):3674-3692.e10. PubMed ID: 30590041
[TBL] [Abstract][Full Text] [Related]
33. Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2.
Heiss E; Masson K; Sundberg C; Pedersen M; Sun J; Bengtsson S; Rönnstrand L
Blood; 2006 Sep; 108(5):1542-50. PubMed ID: 16684964
[TBL] [Abstract][Full Text] [Related]
34. MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling.
Park J; Kim S; Joh J; Remick SC; Miller DM; Yan J; Kanaan Z; Chao JH; Krem MM; Basu SK; Hagiwara S; Kenner L; Moriggl R; Bunting KD; Tse W
Oncotarget; 2016 Jul; 7(28):43960-43973. PubMed ID: 27259262
[TBL] [Abstract][Full Text] [Related]
35. C-terminal Src kinase-mediated EPIYA phosphorylation of Pragmin creates a feed-forward C-terminal Src kinase activation loop that promotes cell motility.
Senda Y; Murata-Kamiya N; Hatakeyama M
Cancer Sci; 2016 Jul; 107(7):972-80. PubMed ID: 27116701
[TBL] [Abstract][Full Text] [Related]
36. Altered glucose homeostasis in mice with liver-specific deletion of Src homology phosphatase 2.
Matsuo K; Delibegovic M; Matsuo I; Nagata N; Liu S; Bettaieb A; Xi Y; Araki K; Yang W; Kahn BB; Neel BG; Haj FG
J Biol Chem; 2010 Dec; 285(51):39750-8. PubMed ID: 20841350
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation.
Zhou X; Agazie YM
J Biol Chem; 2009 May; 284(18):12226-34. PubMed ID: 19261604
[TBL] [Abstract][Full Text] [Related]
38. SHP2 phosphatase promotes mast cell chemotaxis toward stem cell factor via enhancing activation of the Lyn/Vav/Rac signaling axis.
Sharma N; Everingham S; Ramdas B; Kapur R; Craig AW
J Immunol; 2014 May; 192(10):4859-66. PubMed ID: 24733849
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment.
Zhao H; Agazie YM
BMC Cancer; 2015 Mar; 15():109. PubMed ID: 25885600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
